The agenda for the 4 February 2015 Transparency Commission meeting is now available. The Commission will consider the following medicines:

• Olmesartan - review of SMR
• Dibotermin alfa (Inductos) - review of SMR & ASMR
• Obinutuzumab (Gazyvaro) - new medicine
• Liraglutide (Victoza) - review of SMR & ASMR
• Litaglutide (Victoza) - new indication
• Alprostadil (Vitaros) - new formulation

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-01/odj_ct_04022015_internet.pdf [French]